Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05519085 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05519085 · ClinicalTrials.gov record · last posted 2026-08-21

A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Study acronym: SUCCESSOR-1
StatusRecruiting
PhasePhase 3
SponsorCelgene
Started2022-09-20
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The purpose of this study is to compare the efficacy and safety of mezigdomide (CC-92480), bortezomib and dexamethasone (MeziVd) versus pomalidomide, bortezomib and dexamethasone (PVd) in participants with relapsed or refractory multiple myeloma (RRMM) who received between 1 to 3 prior lines of therapy and who have had prior lenalidomide exposure.

Amendment record 149 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 149 times since 2022-08-25; most recent amendment 2026-07-10. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2022-10-12
Status change Not Yet Recruiting→Recruitingv3
Trial Details
NCT Number NCT05519085
Lead Sponsor Celgene
Conditions Relapsed or Refractory Multiple Myeloma
Enrollment 810 participants
Start Date 2022-09-20
Primary Completion 2027-01-10 (estimated)
Study Completion 2033-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-08-21